

Ectopic Expression of Human *DPPA2* Gene in ESCC Cell Line Using Retroviral SystemMaryam Khaleghizadeh^{1,2}, Mohammad Mahdi Forghanifard³, Abolfazl Rad⁴, Moein Farshchian², Zahra Hejazi¹, Mehran Gholamin², Bahram Memar⁵ and Mohammad Reza Abbaszadegan^{2,6*}

1. Department of Microbiology, Damghan Branch, Islamic Azad University, Damghan, Iran

2. Human Genetic Division, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran

3. Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran

4. Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran

5. Department of Pathology, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

6. Medical Genetics Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Background: Cancer/Testis Antigens (CTAs) are a subgroup of tumor-associated antigens which are expressed normally in germ line cells and trophoblast, and aberrantly in a variety of malignancies. One of the most important CTAs is Developmental Pluripotency Associated-2 (DPPA2) with unknown biological function. Considering the importance of DPPA2 in developmental events and cancer, preparing a suitable platform to analyze DPPA2 roles in the cells seems to be necessary.

Methods: In this study, the coding sequence of *DPPA2* gene was amplified and cloned into the retroviral expression vector to produce recombinant retrovirus. The viral particles were transduced to Esophageal Squamous Cell Carcinoma (ESCC) cell line (KYS E-30 cells) and the stable transduced cells were confirmed for ectopic expression of *DPPA2* gene by real-time PCR.

Results: According to the critical characteristics of retroviral expression system such as stable and long time expression of interested gene and also being safe due to deletion of retroviral pathogenic genes, this system was used to induce expression of *DPPA2* gene and a valuable platform to analyze its biological function was prepared. Transduction results clearly showed efficient overexpression of the gene in target cells in protein level due to high level of GFP expression.

Conclusion: Such strategies can be used to produce high levels of desired protein in target cells as a therapeutic target. The produced recombinant cells may present a valuable platform to analyze the effect of DPPA2 ectopic expression in target cells. Moreover, the introduction of its potential capacity into the mouse model to evaluate the tumorigenesis of these cancer cells *in vivo* leads to an understanding of the biological importance of DPPA2 in tumorigenesis. In addition, our purified protein can be used in a mouse model to produce specific antibody developing a reliable detection of DPPA2 existence in any biological fluid through ELISA system.

*Avicenna J Med Biotech 2018; 10(2): 75-82***Keywords:** Carcinogenesis, Esophageal squamous cell carcinoma, Germ cells, Testis

Introduction

Epigenetic modifications such as CpG DNA methylation are widely reprogrammed on a genome during embryogenesis. The embryonic cells of blastocyst, Inner Cell Mass (ICM) and the Primordial Stem Cells (PSCs) are categorized as totipotent stem cells which can differentiate into all different types of individual cells¹⁻³. Cancer cells share many similarities with germ line and embryonic cells, including deprogramming, invasive growth, proliferation, ability to self-renew and maintenance of the undifferentiated cell state. There-

fore, it seems that embryonic active genes may be associated with these features of cancer cells. This hypothesis existed based on the identification of several embryo-cancer transcripts which are expressed in human embryos and absent in normal differentiated somatic cells, but re-expressed in tumor cells^{4,5}. One of these transcripts is Developmental Pluripotency Associated-2 (DPPA2) which subsequently entered into the gene databases as Embryo-Cancer Sequence A (ECSA) and is also known as Cancer Testis Antigen100 (CT100)

^{6,7}. Cancer Testis Antigens (CTAs) are one of the most promising categories of Tumor-Associated Antigens (TAAs) in cancer-therapy, and over 140 members of CTAs, globally accounting for about 70 families, have been identified ⁸⁻¹⁴. The expression of CTAs normally restricted to germ cells in the testes, ovaries or trophoblasts ^{10,15,16}. CTAs are divided into two groups, the X-CTAs which are encoded by the X chromosome and represent about one-half of *CT* genes, and the non-X-CTAs which are distributed throughout the genome and are mostly single-copy genes. It has been estimated that 10% of the genes on the X chromosome belonged to CTAs ^{10,17,18}. The gene encoding *DPPA2* in human maps to chromosome 3q13 over 8 exons and encodes a protein consisting of 297 amino acids. The primary structure of this protein contains a Spliceosome-Associated Protein (SAP) motif and localizes to the nucleus. This gene is expressed in different types of malignancies including lymphoma and lung, ovarian, liver, and colon cancers ^{4,6}.

Few studies have focused on molecular epidemiology of *DPPA2* in cancer ¹⁹, and the biological function of this protein is unclear. Our aim in this study was to produce a stable transduced cell line which constitutively express *DPPA2* gene, helping to understand well about the *DPPA2* biological role. A retroviral expression system was used in packaging cells to achieve high titers of recombinant virus particles. The results presented in this study demonstrate the feasibility of using this approach in expression of *DPPA2* and to survey the function of this protein in any target cells.

Materials and Methods

Gene analysis

The information of *DPPA2* gene was obtained from NCBI database. The main characteristics of the gene such as gene and mRNA lengths, the coding sequence, and the number of probable pseudogenes were analyzed.

Primer design

After analyzing *DPPA2* gene in different databases and a survey for its pseudogenes, cloning primer set1 was designed using GeneRunner software version 3.05 (Hastings Software Inc., Hastings, NY, USA) and checked for probable hairpins, dimers, GC percentage and Tm.

RNA extraction, cDNA synthesis

Having searched protein atlas database (<http://www.proteinatlas.org>), it was shown that *DPPA2* expressed cell lines. The selected cell lines were cultured, harvested, their total RNA were extracted using Trizol reagent (Invitrogen, Carlsbad, CA) and related cDNA was synthesized using oligo dT in first-strand cDNA synthesis kit (Fermentas, Vilnius, Lithuania) according to the manufacture's protocols.

Real time PCR

cDNAs were amplified on the Stratagene Mx-3000P real-time thermocycler (Stratagene, La Jolla, CA) with

Table1. Real time primer set (1), Cloning primer set (2)

Primer	Primer sequences
Forward primer 1	5'- AGAAATACAATCCAGGTCATCTACTTC -3'
Reverse primer 1	5'- GCATATCTTGCCGTTGTTTCAGG -3'
Forward primer 2	5'- TTTTGGATCCCAGGGTGTGCT -3'
Reverse primer 2	5'-TTTCTCGAGGTTGCTGCTACTTC-3'

SYBR green mastermix (Invitrogen, Carlsbad, CA) containing ROX as a reference dye and real time primer set presented in table 1. All experiments were performed in duplicates.

Amplification of *DPPA2* coding sequence

One microliter of cDNA (100 ng of total RNA) was used in PCR reaction with a final concentration of 1 mmol/L magnesium chloride, 0.5 mmol/L deoxynucleoside triphosphate (Fermentas, Vilnius, Lithuania), 0.2 units of Taq DNA polymerase (Fermentas, Vilnius, Lithuania), and 0/3 μ l of each cloning primer set 1 in a final volume of 20 μ l. The PCR condition was 95°C for 5 min followed by 35 cycles of 95°C for 30 s, 55°C for 30 s and 72°C for 45 s.

Cycling was terminated with a final extension step of 7 min at 72°C. PCR products were visualized on a 1% agarose/green viewer gel.

TA cloning of amplified fragment

RT-PCR product was cut off from agarose gel and purified using DNA extraction kit (Invitex GmbH, Berlin, Germany), according to the manufacturer's recommendation. The purified PCR product (5 to 10 ng) was cloned using TA cloning kit (Fermentas, Vilnius, Lithuania), according to the manual provided by the supplier and followed by blue/white selection. 15 colonies of transformed *Escherichia coli* (*E. coli*) *TOP10F'* were picked, cultured, and subjected to colony PCR. Plasmid extraction was done on confirmed recombinant colonies using plasmid extraction kit (GeNet Bio, Chungnam, Korea) and extracted plasmids were confirmed through colony PCR, double digestion with BamHI and XhoI restriction endonucleases and DNA sequencing.

Characteristics of retroviral vector

The retroviral vector backbone used in this study, pRUF-IRES-GFP, is a Murine Leukemia Virus-Based Vector which utilizes a MLV long terminal repeat (LTR). This vector was kindly provided by Dr. Paul Moretti (Hanson Institute, SA, Australia, <http://www.hansoninstitute.sa.gov.au/>).

Sub cloning of amplified fragment in retroviral vector

The pRUF plasmid was double digested with BamHI and XhoI and purified coding fragment of *DPPA2* gene was ligated into the cloning site of pRUF which is cleaved with the same enzymes. After transformation, 10 colonies of transformed *E. coli* *TOP10F'* were picked up, cultured, and subjected to plasmid extraction. The extracted plasmids were confirmed through colony PCR, double digestion with BamHI and XhoI enzymes and DNA sequencing.

Cell lines and culture

GP293 and HEK293 (the Human Embryonic Kidney cells 293T) as packaging cell lines and KYSE-30 [Esophageal Squamous Cell Carcinoma (ESCC) cell line] as target cell line were cultured in DMEM and RPMI 1640, respectively, and both media were supplemented with 10% FBS (Gibco, NY, USA), 1% (*v/v*) penicillin, streptomycin and incubated in an atmosphere of 5% CO₂ at 37°C.

Retroviral vector production

High amount of pRUF-DPPA2, pVSV-G and pGP plasmids were produced in *E. coli* strain *TOP10F'* grown in LB medium supplemented with ampicillin (50 mg/ml). Plasmids were isolated and purified using Jetstar plasmid purification kit (Genomed, Bad Oeynhausen, Germany). Quality and quantity of the plasmids were verified by gel electrophoresis and UV-spectrophotometry. For transfection in 10 cm plate, 100 ng of each recombinant pRUF plasmid, plasmid encoding VSV-G protein and plasmid encoding Gag-Pol proteins were co-transfected into packaging cell lines separately using calcium phosphate method according to Tronolab protocol. Used solutions in this protocol included calcium phosphate: 2.5 M solution in ddH₂O, sterile-filtered, 2× HEPES-Buffered Saline (HBS): (for 500 ml) 8 g NaCl, 0.38 g KCl, 0.1 g Na₂HPO₄, 5 g HEPES, 1 g glucose; pH=7.05, sterile-filtered, MEM C supplemented with 25 mM glucose. This protocol was adapted for 10 cm dishes but it can be adapted to smaller or bigger plates. The timing has also been optimized for our needs but it supports some flexibility. This protocol was done in 5 days. Day 1 (Plating); the day before transfection, HEK293T cells were suspended in 90% DMEM/10% FCS (*v/v*) and seeded into cell-culture dishes of 10 cm in diameter at a density of 2.5-3 million cells/plate. Day 2 (Transfection); transfection was carried out by the calcium phosphate method. For calcium phosphate precipitation (1 ml/90 mm culture dish), 20 µg of transfer vector (pRUF), 15 µg of packaging plasmid (pGP) and 6 µg of envelope plasmid (pVSV-G) were put into a sterile reaction tube in final volume of approximately 150-200 µl. Then 50 µl of 2.5 M calcium chloride solution was added to this plasmid solution. The solution was brought to a volume of 500 µl with autoclaved ddH₂O. After transferring 500 µl of double-concentrated HBS solution to another reaction tube, the calcium chloride solution was added to the HBS solution very slowly (dropwise), and the solution was mixed. Incubation at room temperature for 1 min was followed by dropwise addition of the precipitate to the cells under gentle shaking of the plate. The plate was then incubated at 37°C in a humidified atmosphere of 95% air and 5% CO₂. After 6-8 hr of transfection, the calcium phosphate precipitate-containing medium was removed and the cells were washed briefly with 5 ml of 90% DMEM/10% FCS (*v/v*), then 6 ml of fresh MEMC supplemented with 25 mM glucose were added

and the plate was incubated at 37°C in a humidified atmosphere of 95% air and 5% CO₂. Days 3, 4 and 5 (Collection of virus); transfected cells were examined under an inverted fluorescence microscope (Olympus IX-70). A narrow band of GFP filter set (exciter D480/20; emitter D520/20; Chroma, Brattleboro, VT) was used to detect the expression of the GFP in the cells. The virus-containing supernatant was harvested into a sterile tube, centrifuged (3000 rpm, 5 min, RT), filtered through a 0.45 µm mesh filter and stored at 4°C. Then the supernatant was ultracentrifuged in the SW28 rotor (Beckman Instruments, Fullerton, CA, USA) at 73000 g at 4°C for 2 hr to pellet the virus. After ultracentrifugation, the supernatant was aspirated and the pelleted virus was resuspended in a small volume of cultivation medium and stored in aliquots at -80°C. Transfection of 293GP cells was carried out using the same protocol as HEK-293 cells but just with DPPA2-pRUF and pVSV-G plasmids.

Transduction of target cells by enriched recombinant viral particles

For transduction in a six-well plate, cells were seeded prior to the day for transduction. One ml of virus supernatant was mixed with 1 ml of fresh RPMI/10% FBS containing 1% pen/strep and added to wells. The cell culture medium was changed 5-10 hr after transduction. For detection of GFP expression, transduced cells were harvested 36-48 hr after transduction. Cells were examined under an inverted fluorescence microscope (Olympus IX-70, Tokyo, Japan). A narrow band of GFP filter set (exciter D480/20; emitter D520/20; Chroma, Brattleboro, VT) was used to detect the expression of the GFP in the cells.

Titration of retroviral vector by quantitative PCR (qPCR)

KYSE-30 cells were transduced and the DNA was extracted using a genomic DNA extraction kit (Qiagen, Hilden, Germany). A fraction of this DNA was then analyzed for copy number of retroviral sequences using the Tronolab real-time PCR protocol. It measured the number of retroviral DNA copies integrated in the target cell genome. The ultimate test of the functionality of the vector was in cells supporting the activity of the promoter driving the transgene. Titration of retroviral particles was performed according to Tronolab protocol²⁰. Firstly, a mix (containing everything but the sample DNA) for the number of wells needed for the qPCR analysis, including all samples and standards in duplicates according to the following recipe (9 µl per well) was prepared: 10 µl SYBR green PCR Master Mix (Fermentas, Lithuania) and 1 µl forward/reverse mix primer (10 pM). Then, 2 µl of sample DNA to each of the appropriate wells was added. The amplification cycles used were: 1 cycle: 10 min 95 °C, then 40 cycles: 15 s 95 °C, 30 s 60 °C and 20 s 72 °C. pAlb (available from Addgene, <http://www.addgene.org>) was a pRRL vector in which the target sequence of the albumin primers used for normalization has been cloned. This

Table 2. Primers for retrovectors' titration by qPCR

Sequence detected	Primer name	Primer sequence
Gag	Gag forward	GGAGCTAGAACGATTTCGAGTTA
	Gag reverse	GGTGTAGCTGTCCCAGTATTGTC
Albumin	Alb forward	GCTGTCATCTCTTGTGGGCTGT
	Alb reverse	ACTCATGGGAGCTGCTGGTTC

plasmid allows performing a standard curve. Gag oligos were used for amplification of pRUF vector sequence and were specific for the 5' end of the *gag* gene. This sequence was present in pRUF vector, as it was part of the extended packaging signal. Alb oligos were used to normalize the amount of genomic DNA and were specific for the human albumin gene (Table 2). Also cells were examined under an inverted fluorescence microscope (Olympus IX-70). A narrow band of GFP filter set (exciter D480/20; emitter D520/20; Chroma, Brattleboro, VT) was used to detect the expression of the GFP in the cells.

Results

Gene analysis and primer design

DPPA2 gene was analyzed using NCBI database. The mRNA length of the gene is 1393 bp containing 9 exons. The coding region on mRNA is from 248 to 1144 bp which encodes 298aa. A pseudogene was found for *DPPA2* coding sequence which is important in primer design. Alignment between the gene and its pseudogene was done using CLC work bench software version 5.6 (CLC bio, Aarhus, Denmark), and the percentage of homology was 92%. Since the length of pseudogene was 248 bp shorter than the *DPPA2* mRNA at 5' end and due to the similar sequences of primary regions, forward primer designed 4 nucleotides before the ATG initiation codon. Having analyzed the gene sequence, a cloning primer set presented in table 1 was designed. By substitution of 2 and 3 nucleotides, restriction sites were induced for BamHI (GGA-TCC) and XhoI (CTCGAG) in forward and reverse primers, respectively (Table 1).

RNA extraction, cDNA synthesis

Five cell lines including SKOV3, NCCIT, HEK293, Hela and HT that expressed *DPPA2* gene were found using protein atlas site. Full length complementary DNA (cDNA) of *DPPA2* coding sequence was synthesized from the total RNA extracted from SKOV3, NCCIT, HEK293, Hela, HT cell lines. cDNA of SKOV3 cell line was also synthesized by downstream primer.

Real time PCR

The expression level of *DPPA2* in these cell lines was determined using real time PCR. The results revealed that SKOV3 cell line has higher expression level than others.




Figure 1. PCR amplification of *DPPA2*. PCR product was 941 bp long as expected when visualized on agarose gel.

Reverse transcription-polymerase chain reaction (RT-PCR) assay

cDNA was amplified with gene specific primers by standardized PCR conditions. Resulting fragment of *DPPA2* was 941 bp in size as expected when visualized on agarose gel (Figure 1).

TA cloning

The amplified product was used for ligation in pTZ57R/T cloning vector. The basis for ligation of any PCR product in this vector is the presence of overhanged adenines at both 3' and 5' ends of PCR product which binds complementary with thymine present at MCS of the linearized vector during ligation process.

Transformation of *E. coli* with pTZ57R/T *DPPA2* vector

Competent cells of *E. coli* strain, *TOP10F'*, were transformed with pTZ57R/TDPPA2 vector using *cacl2* method. Insertion of *DPPA2* cDNA in multiple cloning sites of pTZ57R/T caused inactivation of *Lac Z* gene hence white colonies were produced on selection with X-Gal/IPTG containing media plates. Single transformed white colonies were further used for colony PCR and plasmid extraction. The size of pTZ57R/T is 2886 bp which was increased to 3827 bp after insertion of *DPPA2* fragment and visualized by agarose gel electrophoresis.

Confirmation of *DPPA2* through colony PCR, restriction digestion and sequencing

After confirming through colony PCR, the recombinant plasmid was extracted and digested with BamHI and XhoI resulting in release of about 941 bp fragment which was separated on 1% agarose gel (Figure 2). Finally, the sequence of PCR product in pTZ57R/TDPPA2 vector was confirmed by sequencing.

Sub cloning of *DPPA2* gene in pRUF expression vector

Competent cells of *E. coli* strain, *TOP10F'*, were transformed with pRUF*DPPA2* vector. 10 colonies of transformed *E. coli* were chosen and confirmed through colony PCR and double digested with BamHI and XhoI enzymes. The size of pRUF is 5950 bp which was increased to 6891 bp after insertion of *DPPA2* cDNA and visualized by agarose gel electrophoresis.




Figure 2. Recombinant pTZ57R/TDPPA2 digested with BamHI and XhoI. Digestion of recombinant pTZ57R/TDPPA2 gives 2 bands that correspond to pTZ57R/T vector (2886 bp) and DPPA2 gene (941 bp).

After extraction of pRUF-DPPA2 vector, this recombinant plasmid was digested with BamHI and XhoI resulting in release of about 941 bp fragment which was separated on 1% agarose gel to confirm the size (Figure 3).

Retroviral vector production

The pRUF plasmid is an expression vector containing GFP gene as a reporter gene, Internal Ribosome Entry Site (IRES), ampicillin resistant gene and restriction site for BamHI and XhoI enzymes (Figure 4).

Recombinant pRUF-IRES-GFP was transiently co-transfected along with the plasmids encoding VSV-G and Gag-Pol proteins into the HEK293 packaging cells. Cells were examined under an inverted fluorescence microscope (Olympus IX-70, Tokyo, Japan). A narrow band of GFP filter set (exciter D480/20; emitter D520/20; Chroma, Brattleboro, VT) was used to detect the expression of the GFP in the cells. The efficiency of transfection was about 10%. Recombinant pRUF with VSV-G plasmid were cotransfected into 293GP packaging cells which express gag and pol genes. The




Figure 4. pRUF Retroviral Vector Map. This image was kindly provided by Paul Moretti, Hanson Institute, SA, Australia, <http://www.hansoninstitute.sa.gov.au/>

efficiency of transfection into 293GP was about 70% that was higher than HEK293 retroviral packaging cells (Figures 5A and 5B). These percentages were determined by measurement of GFP expression by flow-cytometry analysis (data not shown). Viral supernatants were collected and used to infect KYSE-30 cells (Figure 5C). After transduction, viral titers were determined by quantitative PCR (qPCR), and virus stocks containing $10^5 TU/ml$ were obtained (Figure 6).

Discussion

Deprogramming or removal of the epigenetic information returns the cell to the undifferentiated stem cell state²¹⁻²⁵. Embryonic genes which are active in pluripotent embryonic stem cells may be associated with




Figure 3. Sub cloning of DPPA2 gene in pRUF expression vector, A. Negative control plate; B. Sub cloning plate of DPPA2 gene; C. Colony PCR for confirming recombinant colonies, D. The size of pRUF vector was increased to 6891 bp after insertion of DPPA2 gene, E. Digestion of recombinant pRUF-DPPA2 plasmid by BamHI and XhoI gives 2 bands that correspond to Pruf expression vector (5950 bp) and DPPA2 gene (941 bp).




Figure 5A-C. GFP expression in target cells 48 hr after transfection ($\times 100$) that were representative fluorescent photographs of HEK293T and GP293, respectively, under fluorescent microscope. 6C was representative fluorescent photograph of target cell (KYSE-30) that was transduced by enriched recombinant viral particles.




Figure 6. Titer estimation of retroviral vector using real-time RT-PCR. Serial dilutions of pAlb vector were prepared. A) Amplification plot of samples with each dilution was represented in order from left to right on the graph. B) Standard curve generated from amplification plot is shown in A. Each sample was performed in duplicate and is represented as a dot. Overlapping dots are present in most of the dilutions illustrating the tight correlation within each dilution. Correlation coefficient for Alb and Gag was 103.3 and 99.5%, respectively.

similar properties presented in cancer cells involving deprogramming, unlimited proliferation, maintenance of the undifferentiated cell state, invasiveness as well as the ability to self-renew. Therefore, cancer cells may resemble stem cells through common functions and signals to initiate and progress deprogramming^{4,5}. Many cancers are associated with reactivation of germ cell and embryonic genes, e.g. the so-called *Cancer/Testis (CT)* genes or *CG* genes^{14,15,26,27}. ECSA/DPPA2, also known as CT100, is a human embryonic antigen that is predominantly expressed in NSCLC (Non-small cell lung carcinoma) and also in other malignancies including melanoma, lymphoma, and in lung, liver and

colorectal cancers^{6,28}. This may confirm involvement of embryonic stem cell properties in the cancer cells or/and cancer stem cell phenotype²⁸. Although the biological functions of this gene are not clear, ectopic expression of this transcription factor can help to understand the functional activity of this gene in the proliferation and maintenance of stem cell activity of cancer cells.

Up to now, several cell-targeting strategies have been developed to obtain the efficient mechanism for delivery of an interested gene to a particular target cell and operating its ectopic expression *in vitro*. Nucleic acids introduction into the target cells may be a medical purpose, and currently, different gene therapy studies are being developed^{29,30}. Since efficient expression of gene of interest in target cell is an essential step, integration of the gene into the host genome can lead to a long-term gene expression³¹. Although several viral vectors have been developed for this reason, retroviral vectors may present promising qualities including large packaging size, long-term expression, capacity for cell targeting and scalable production^{32,33}.

pRUF expression vector, as a retroviral vector, is a Murine Leukemia Virus-Based Vector. Retroviral vectors are needed for packaging cells such as HEK293 or GP293. In this study, pRUF expression vector along with pVSV-G and pGP plasmids were cotransfected to packaging cells. The results presented here indicate that the efficiency of transfection to HEK293 is lower than GP293 cell line. GP293 is a packaging cell that stably expresses Gag-Pol protein, so efficiency of transfection to GP293 is higher than HEK293. Several groups have recently reported the generation of high-titer retroviral particles using transient transfection systems. pRUF contains an extended packaging signal, which is believed to be important for generating high-titer viral preparations. To evaluate and monitor the gene transfer efficiency of these retroviral vectors, a *GFP* gene in this retroviral vector existed that exhibited fluorescence and was easily detected by fluorescence microscopy. pRUF is an IRES-GFP vector and *GFP* works as a reporter gene for monitoring and evaluation of viral transduction efficiency. By this retroviral vector system, there is no need to do western blotting and IHC assays for confirming the expression of interested gene.

In this research, *DPPA2* gene was amplified and isolated by RT-PCR and the efficiency of cloning was increased by using TA cloning. The universal TA cloning method relies on the supposition that all DNA fragments can be easily converted to double stranded DNA with over hanged adenines at both 3' ends, and thus the T-vector becomes a ready-for-ligation universal cloning vector.

Our transduction results clearly showed efficient over expression of the gene in target cells in protein level due to high level of GFP expression. Such strategy can be used to produce high level of desired protein in tar-

get cell as a therapeutic target. Interestingly, different cellular and molecular biology approaches (such as real-time PCR for gene expression pattern profiling, and proliferation and migration assay for analysis of cell behavior), can be developed to analyze the effect of protein ectopic expression in target cells. Furthermore, the produced cells with ectopic expression of target gene can be introduced to the mouse model to evaluate the tumorigenesis of these cancer cells *in vivo*, leading to an understanding of the biological importance of DPPA2 in tumorigenesis. In addition, purified protein can be used in a mouse model to produce specific antibody, developing a reliable detection of DPPA2 existence in any biological fluid through ELISA system.

Conclusion

In summary, *DPPA2* gene was successfully subcloned and expressed in pRUF expression vector, and by producing a recombinant retrovirus, *DPPA2* gene was transduced and expressed in KYSE-30 cell as a target cell. Since the function of DPPA2 is not clear, it can be used for understanding the biological function of this cancer testis antigen. Also, the recombinant DPPA2 protein that was produced by this recombinant retrovirus can be used in production of recombinant vaccines.

Acknowledgement

This study was a MSc thesis and supported by a grant from Mashhad University of Medical Sciences, Mashhad, Iran (# 910314).

References

- Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. *Nature* 1981; 292(5819):154-156.
- Matsui Y, Zsebo K, Hogan BL. Derivation of pluripotential embryonic stem cells from murine primordial germ cells in culture. *Cell* 1992;70(5):841-847.
- Shi L, Wu J. Epigenetic regulation in mammalian pre-implantation embryo development. *Reprod Biol Endocrinol* 2009;7:59.
- Monk M, Holding C. Human embryonic genes re-expressed in cancer cells. *Oncogene* 2001;20(56):8085-8091.
- Ma Y, Zhang P, Wang F, Yang J, Yang Z, Qin H. The relationship between early embryo development and tumorigenesis. *J Cell Mol Med* 2010;14(12):2697-2701.
- John T, Caballero OL, Svobodová SJ, Kong A, Chua R, Browning J, et al. ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer. *Clin Cancer Res* 2008;14(11):3291-3298.
- Tung PY, Varlakhanova NV, Knoepfler PS. Identification of DPPA4 and DPPA2 as a novel family of pluripotency-related oncogenes. *Stem Cells* 2013;31(11):2330-2342.
- van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. *Science* 1991;254(5038):1643-1647.
- Juretic A, Spagnoli GC, Schultz-Thater E, Sarcevic B. Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. *Lancet Oncol* 2003;4(2):104-109.
- Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. *Nat Rev Cancer* 2005;5(8):615-625.
- Costa FF, Le Blanc K, Brodin B. Concise review: cancer/testis antigens, stem cells, and cancer. *Stem Cells* 2007;25(3):707-711.
- Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, et al. Genome-wide analysis of cancer/testis gene expression. *Proc Natl Acad Sci USA* 2008; 105(51):20422-20427.
- Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. *Cancer Sci* 2009;100(11):2014-2021.
- Lim SH, Zhang Y, Zhang J. Cancer-testis antigens: the current status on antigen regulation and potential clinical use. *Am J Blood Res* 2012;2(1):29-35.
- Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. *Immunol Rev* 2002;188:22-32.
- Scanlan MJ, Simpson A, Old LJ. The cancer/testis genes: review, standardization, and commentary. *Cancer Immun* 2004;4:1.
- Ross MT, Grafham DV, Coffey AJ, Scherer S, McLay K, Muzny D, et al. The DNA sequence of the human X chromosome. *Nature* 2005;434(7031):325-337.
- Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R, et al. The biology of cancer testis antigens: putative function, regulation and therapeutic potential. *Mol Oncol* 2011;5(2):164-182.
- Raeisossadati R, Abbaszadegan MR, Moghbeli M, Tavassoli A, Kihara AH, Forghanifard MM. Aberrant expression of DPPA2 and HIWI genes in colorectal cancer and their impacts on poor prognosis. *Tumor Biol* 2014; 35(6):5299-5305.
- Barde I, Salmon P, Trono D. Production and titration of lentiviral vectors. *Curr Protoc Neurosci* 2010;Chapter 4:Unit 4.21.
- Monk M, Boubelik M, Lehnert S. Temporal and regional changes in DNA methylation in the embryonic, extra-embryonic and germ cell lineages during mouse embryo development. *Development* 1987;99(3):371-382.
- Mayer W, Niveleau A, Walter J, Fundele R, Haaf T. Demethylation of the zygotic paternal genome. *Nature* 2000;403(6769):501-502.
- Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. *Science* 2001;293(5532):1089-1093.
- Smith AG. Mouse embryo stem cells: their identification, propagation and manipulation. *Semin Cell Biol* 1992;3(6):385-399.

Ectopic Expression of *DPPA2* Gene

25. Loscalzo J, Handy DE. Epigenetic modifications: basic mechanisms and role in cardiovascular disease (2013 Grover Conference series). *Pulm Circ* 2014;4(2):169-174.
26. Old LJ. Cancer/testis (CT) antigens - a new link between gametogenesis and cancer. *Cancer Immun* 2001;1:1.
27. Koslowski M, Bell C, Seitz G, Lehr HA, Roemer K, Müntefering H, et al. Frequent nonrandom activation of germ-line genes in human cancer. *Cancer Res* 2004;64(17):5988-5993.
28. Monk M, Hitchins M, Hawes S. Differential expression of the embryo/cancer gene ECSA (*DPPA2*), the cancer/testis gene BORIS and the pluripotency structural gene OCT4, in human preimplantation development. *Mol Hum Reprod* 2008;14(6):347-355.
29. Coleman JE, Huentelman MJ, Kasparov S, Metcalfe BL, Paton JF, Katovich MJ, et al. Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. *Physiol Genomics* 2003;12(3):221-228.
30. O'Keefe EP. Nucleic acid delivery: lentiviral and retroviral vectors. *Labome.com*. 2013.
31. Sinn P, Burnight ER, McCray PB Jr. Progress and prospects: prospects of repeated pulmonary administration of viral vectors. *Gene Ther* 2009;16(9):1059-1065.
32. Hu WS, Pathak VK. Design of retroviral vectors and helper cells for gene therapy. *Pharmacol Rev* 2000;52(4):493-512.
33. Escors D, Kochan G, Stephenson H. Development of retroviral and lentiviral vectors. In: Escors D, Breckpot K, Arce F, Kochan G, Stephenson H, editors. *Lentiviral vectors and gene therapy*. New York: Springer; 2012. p. 11-28.